Trial Profile
A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) With or Without Ipilimumab (BMS-734016) in Patients With Advanced Renal Cell Carcinoma in Real Life Setting
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms WITNESS
- Sponsors Bristol-Myers Squibb
- 26 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2022 Results of pooled analysis from WITNESS (NCT03455452) and NORA (NCT02940639) assessing baseline characteristics and to assess overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety in the subgroup of pts with nccRCC, after a minimum follow-up of 14.1 months presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results as a part of the IO-Synthesise RCC, from NCT03455452 and NCT02940639, reporting HRQoL outcomes for patients receiving NIVO for previously treated mRCC , presented at the 47th European Society for Medical Oncology Congress